Oxaliplatine, acide folinique et 5-fluorouracile (folfox) en seconde ligne thérapeutique du cancer colorectal métastasé

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Revue de Médecine Interne

• Publication date

  1997-10-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/S0248-8663(97)89966-3
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.

  1997cited by this paper
• Bimonthly high dose leucovorin and 5‐fluorouracil 48‐hour continuous infusion in patients with advanced colorectal carcinoma

  1997cited by this paper
• Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.

  1997cited by this paper
• Bimonthly high dose leucovorin and 5‐fluorouracil 48‐hour infusion with interferon‐alpha‐2a in patients with advanced colorectal carcinoma

  1997cited by this paper
• Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer.

  1996cited by this paper
• Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.

  1996cited by this paper
• Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate.

  1993cited by this paper
• A chronopharmacologic phase II clinical trial with 5‐fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

  1992cited by this paper
• Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer.

  1991cited by this paper
• A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.

  1989cited by this paper
• Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum.

  1989cited by this paper
• Synergistic action of high‐dose hydroxyurea when used with cyglophosphamide and certain new organoplatinum complexes in treatment of advanced L1210 leukemia

  1978cited by this paper

• Perioperative safety and tolerability of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) with concurrent systemic therapy in the same admission as a bidirectional chemotherapy: A retrospective comparative study.

  2026cites this paper
• Curcumin, calebin A and chemosensitization: How are they linked to colorectal cancer?

  2023cites this paper
• Impact of air temperature and drug concentration on liquid emission from elastomeric pumps

  2021cites this paper
• A comparative analysis of the mutagenicity of platinum-containing chemotherapeutic agents reveals direct and indirect mutagenic mechanisms

  2021cites this paper
• Cisplatin is more mutagenic than carboplatin or oxaliplatin at equitoxic concentrations

  2020cites this paper
• Molecular Markers for Colorectal Cancer.

  2017cites this paper
• Applications of hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer

  2017cites this paper
• Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Methodology, Drugs and Bidirectional Chemotherapy

  2016cites this paper
• Aqueous extract of Lithospermi radix attenuates oxaliplatin-induced neurotoxicity in both in vitro and in vivo models

  2016cites this paper
• Epidemiology, Management, and Survival of Peritoneal Carcinomatosis from Colorectal Cancer: A Population-Based Study

  2015cites this paper
• Rationale for Integrated Procedures: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined

  2015cites this paper
• Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy

  2012cites this paper
• Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer

  2011cites this paper
• Hepatic arterial infusion of bevacizumab in combination with oxaliplatin reduces tumor growth in a rat model of colorectal liver metastases

  2011cites this paper
• Tumeurs digestives : côlon — rectum

  2011cites this paper
• Pharmacology of perioperative 5‐Fluorouracil

  2010cites this paper
• A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.

  2010cites this paper
• Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix.

  2009cites this paper
• Pharmacokinetics and Pharmacodynamics of Perioperative Cancer Chemotherapy in Peritoneal Surface Malignancy

  2009cites this paper
• [Antiangiogenic therapy for gastrointestinal tumors].

  2008cites this paper
• Advances in Chemotherapy against Advanced or Metastatic Colorectal Cancer

  2008cites this paper
• Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer.

  2008cites this paper
• Intra arterial hepatic chemotherapy for unresectable colorectal metastases: (review).

  2007cites this paper
• A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer

  2007cites this paper
• Logistic regression model of the clinical response to 5-fluorouracil based chemotherapy for metastatic colorectal cancer patients.

  2006cites this paper
• Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX 6 and 7) Regimens for Colorectal Cancer

  2005cites this paper
• FOLFOX versus FOLFIRI: a comparison of regimens in the treatment of colorectal cancer metastases.

  2005cites this paper
• Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy.

  2005cites this paper
• A panel discussion of controversies and challenges in the adjuvant treatment of colon cancer

  2005cites this paper
• Oxaliplatin/5-FU without leucovorin chemotherapy in metastatic colorectal cancer.

  2005cites this paper
• Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.

  2005cites this paper
• Medical treatment of advanced colorectal carcinoma

  2004cites this paper
• Geraniol, a component of plant essential oils, modulates DNA synthesis and potentiates 5-fluorouracil efficacy on human colon tumor xenografts.

  2004cites this paper
• Second-line treatment in advanced colon cancer: are multiple phase II trials informative enough to guide clinical practice?

  2003cites this paper
• Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer.

  2003cites this paper
• Prospective Pilot Study of Neoadjuvant Chemotherapy with 5-Fluorouracil, Folinic Acid and Oxaliplatin in Resectable Liver Metastases of Colorectal Cancer. Analysis of 42 Neoadjuvant Chemotherapies*

  2003cites this paper
• Metastatic colorectal cancer: systemic treatment in the new millennium.

  2003cites this paper
• Internet pharmaco-economic studies in metastatic colorectal cancer.

  2001cites this paper
• Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.

  2000cites this paper
• Oxaliplatin pharmacokinetics during a four-hour infusion.

  1999cites this paper
• Oxaliplatine (1R, 2R-diaminocyclohexane) : Mécanisme d'action, activité préclinique et clinique

  1999cites this paper
• Oxaliplatin: a review of its use in the management of metastatic colorectal cancer.

  1999cites this paper